A novel CpG-based signature for survival prediction of lung adenocarcinoma patients

Rongjiong Zheng; Haiqi Xu; Wenjie Mao; Zhennan Du; Mingming Wang; Meiling Hu; Xiaolong Gu

doi:10.3892/etm.2019.8200

A novel CpG-based signature for survival prediction of lung adenocarcinoma patients

Exp Ther Med. 2020 Jan;19(1):280-286. doi: 10.3892/etm.2019.8200. Epub 2019 Nov 15.

Authors

Rongjiong Zheng¹, Haiqi Xu¹, Wenjie Mao¹, Zhennan Du¹, Mingming Wang¹, Meiling Hu², Xiaolong Gu¹

Affiliations

¹ Department of Pulmonology, Ningbo Yinzhou Second Hospital, Ningbo, Zhejiang 315192, P.R. China.
² Department of Surgery, Cixi People's Hospital of Zhejiang Province, Ningbo, Zhejiang 315300, P.R. China.

Abstract

Lung adenocarcinoma (LACA) is the leading cause of cancer-associated death worldwide. The present study intended to identify DNA methylation patterns that may serve as diagnostic and prognostic biomarkers for LACA. Data on DNA methylation and the survival data of the patients of LACA were obtained from The Cancer Genome Atlas. Kaplan-Meier curves and receiver operating characteristic curve analysis were utilized to build diagnostic and prognostic models. A total of 13 CpG sites were identified and validated as the optimal diagnostic and prognostic signature for overall survival. It was concluded that the CpG-based signature is a reliable predictor for the diagnosis and prognosis of patients with LACA.

Keywords: lung adenocarcinoma; methylation; prognostic signature.